"Obesity contributes to worsening heart failure, and while tirzepatide causes considerable weight loss, research is lacking ...
SUMMT has shown for the first time that a drug can reduce major heart failure clinical outcomes in patients with heart ...
GlobalData on MSN6h
Eli Lilly reports outcomes from Phase III trial of tirzepatide for HFpEFThe trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.
The results from the SUMMIT trial of tirzepatide in obese patients with heart failure ... a nearly 25-point improvement in ...
HF specialists agree these drugs will be key tools in fighting the obesity-related HFpEF epidemic. Hurdles and questions ...
Spanning 176 weeks of treatment, the Phase III trial evaluated the efficacy and safety of tirzepatide in adults without type ...
Medpage Today on MSN2d
Tirzepatide Officially Puts GLP-1 Meds on the Map for Obesity-Related Heart FailureA long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and accompanying ...
News Medical on MSN2h
Tirzepatide improves heart health and function in obese HFpEF patientsIn the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking tirzepatide for up to 3 years had a reduced combined risk of worsening heart failure ...
Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...
The detailed results were published in The New England Journal of Medicine and were presented at ObesityWeek 2024.
Obesity is a chronic condition and a key risk factor for a range of other health issues, including type 2 diabetes. In a ...
Eli Lilly and Co. (LLY) has released detailed findings from the Phase 3 SUMMIT trial, demonstrating that tirzepatide significantly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback